Emma Walmsley, GlaxoSmithKline CEO (Mandel Ngan/AFP via Getty Images)

GSK falls in line with Big Phar­ma's re­ac­tion to Ukraine in­va­sion, cut­ting off new clin­i­cal tri­als, do­nat­ing prof­its and more

Just a few days af­ter mul­ti­ple Big Phar­mas such as Bay­er and Pfiz­er start­ed the de-fac­to Big Phar­ma re­sponse to Russ­ian ag­gres­sion in Ukraine, oth­er glob­al play­ers such as No­var­tis and Eli Lil­ly start­ed to fol­low suit, push­ing be­yond its first ten­ta­tive steps with a full-throat­ed com­mit­ment to sev­er­ing busi­ness ties with Rus­sia wher­ev­er pos­si­ble.

Now an­oth­er one of the hand­ful of hold­outs is pil­ing on: Lon­don-based Glax­o­SmithK­line. The phar­ma — helmed by Em­ma Walm­s­ley — an­nounced overnight that the com­pa­ny has tak­en a few ac­tions in Rus­sia, say­ing:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.